Lobenzarit Attenuates DSS-Induced Colitis by Reprogramming Immune Microenvironment and Mitochondrial Homeostasis
Pharmaceuticals · 12.06.2026 · 19 (6) · 926
DOI: 10.3390/ph19060926 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 12.06.2026. Verfasst von Ali Khaled und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The incidence of inflammatory bowel disease (IBD) is growing in the population. At present, the etiology of inflammatory bowel disease remains unclear, and there is no effective and low-toxic therapeutic drug. This study aimed to investigate the role of Lobenzarit (Lbz) in the treatment of colitis in mice as well as the underlying mechanism.
Methods
In this experiment, colitis was induced in mice with dextran sulphate sodium (Dss). Subsequently, the role of Lbz in colitis and its underlying mechanisms were examined using H&E staining, TEM, ELISA, PCR, and other assays.
Results
Lbz significantly attenuated the related symptoms of Dss-induced colitis in mice. In addition, Lbz suppressed neutrophil infiltration and restored macrophage polarization towards an anti-inflammatory state. Lbz also inhibited (p < 0.05) the activation of signaling pathways TLR4 and MAPK (51.61% decrease for TLR4 and 56.94% decrease for MAPK), reduced the release of inflammatory factors as it significantly decreased (p < 0.05) colonic IL-1β, TNF-α, IFN-γ, COX2, and VEGF (47.63, 42.49, 53.42, 58.74, and 61.28% decreases respectively) thereby attenuating the inflammatory response in mice. Lbz administration also restored the permeability of the intestinal barrier by increasing (p < 0.05) tight junction-associated proteins (claudin-1, occludin, and ZO-1 with a 5.36- and 2.26-fold increase for claudin-1 and ZO-1, respectively) and decreasing (p < 0.05) MALK levels by 53.51%. In addition, Lbz upregulated colonic Cytochrome C oxidase II, PDH, and ATP synthase levels and upregulated CD163, CD206, c-Maf, and PPAR-γ levels as compared to the DSS-treated group.
Conclusions
Lbz has a repairing effect on Dss-induced colitis and may alleviate Dss-induced colitis by targeting the TLR4 pathway and promoting intestinal stem cell proliferation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.
- Department of Pharmacology, Faculty of Pharmacy, Al-Nisour University, Baghdad 10001, Iraq.
- Faculty Health Science Technology, Mansoura National University, Gamasa 7731168, Egypt.
ORCID-Profile: Manar A Nader, Marwa E Abdelmageed
Zitieren
APA
Khaled, A., Nader, M. A., & Abdelmageed, M. E. (2026). Lobenzarit Attenuates DSS-Induced Colitis by Reprogramming Immune Microenvironment and Mitochondrial Homeostasis. Pharmaceuticals, 19(6), 926. https://doi.org/10.3390/ph19060926
Vancouver
Khaled A, Nader MA, Abdelmageed ME. Lobenzarit Attenuates DSS-Induced Colitis by Reprogramming Immune Microenvironment and Mitochondrial Homeostasis. Pharmaceuticals. 2026;19(6):926. doi:10.3390/ph19060926
BibTeX
@article{Khaled2026,
author = {Khaled, Ali and Nader, Manar A and Abdelmageed, Marwa E},
title = {Lobenzarit Attenuates DSS-Induced Colitis by Reprogramming Immune Microenvironment and Mitochondrial Homeostasis},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {6},
pages = {926},
doi = {10.3390/ph19060926}
}
EUVIMED